References
- Toller W, Heringlake M, Guarracino F, et al. Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion. Int J Cardiol 2015;184:323-36
- O’Brien MM, Shroyer AL, Moritz TE, et al.; VA Cooperative Study Group on Processes, Structures, and Outcomes of Care in Cardiac Surgery. Relationship between processes of care and coronary bypass operative mortality and morbidity. Med Care 2004;42:59-70
- Mebazaa A, Pitsis AA, Rudiger A, et al. Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery. Crit Care 2010;14:201
- Algarni KD, Elhenawy AM, Maganti M, et al. Decreasing prevalence but increasing importance of left ventricular dysfunction and reoperative surgery in prediction of mortality in coronary artery bypass surgery: trends over 18 years. J Thorac Cardiovasc Surg 2012;144:340-6
- Ding W, Ji Q, Shi Y, et al. Predictors of low cardiac output syndrome after isolated coronary artery bypass grafting. Int Heart J 2015;56:144-9
- Legare JF, Hirsch GM, Buth KJ, et al. Preoperative prediction of prolonged mechanical ventilation following coronary artery bypass grafting. Eur J Cardiothorac Surg 2001;20:930-6
- Gillies M, Bellomo R, Doolan L, et al. Bench-to-bedside review: Inotropic drug therapy after adult cardiac surgery – a systematic literature review. Crit Care 2005;9:266-79
- Teerlink JR, Metra M, Zacà V, et al. Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. Heart Fail Rev 2009;14:243-53
- Carl M, Alms A, Braun J, et al.; German Society for Thoracic and Cardiovascular Surgery; German Society of Anaesthesiology and Intensive Care Medicine. Guidelines for intensive care in cardiac surgery patients: haemodynamic monitoring and cardio-circulatory treatment guidelines of the German Society for Thoracic and Cardiovascular Surgery and the German Society of Anaesthesiology and Intensive Care Medicine. Thorac Cardiovasc Surg 2007;55:130-48
- Nielsen DV, Hansen MK, Johnsen SP, et al. Health outcomes with and without use of inotropic therapy in cardiac surgery: results of a propensity score-matched analysis. Anesthesiology 2014;120:1098-108
- Papp Z, Édes I, Fruhwald S, et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol 2012;159:82-7
- Leprán I, Pollesello P, Vajda S, et al. Preconditioning effects of levosimendan in a rabbit cardiac ischemia-reperfusion model. J Cardiovasc Pharmacol 2006;48:148-52
- Nieminen MS, Fruhwald S, Heunks LM, et al. Levosimendan: current data, clinical use and future development. Heart Lung Vessels 2013;5:227-45
- Eriksson HI, Jalonen JR, Heikkinen LO, et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Ann Thorac Surg 2009;87:448-54
- De Hert SG, Lorsomradee S, Cromheecke S, et al. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg 2007;104:766-73
- Levin R, Degrange M, Del Mazo C, et al Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Exp Clin Cardiol 2012;17:125-30
- Harrison RW, Hasselblad V, Mehta RH, et al. Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth 2013;27:1224-32
- Landoni G, Biondi-Zoccai G, Greco M, et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med 2012;40:634-46
- Huang X, Lei S, Zhu MF, et al. Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials. J Zhejiang Univ Sci B 2013;14:400-15
- Cleland JG, Takala A, Apajasalo M, et al. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial. Eur J Heart Fail 2003;5:101-8
- de Lissovoy G, Fraeman K, Teerlink JR, et al. Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study. Eur J Health Econ 2010;11:185-93
- Lucioni C, D’Ambrosi A, Mazzi S, et al. Economic evaluation of levosimendan versus dobutamine for the treatment of acute heart failure in Italy. Adv Ther 2012;29:1037-50
- Nieminen MS, Buerke M, Parissis J, et al. Pharmaco-economics of levosimendan in cardiology: A European perspective. Int J Cardiol 2015;199:337–41
- Institute for Quality and Efficiency in Health Care. Working Paper: Cost Estimation. 2009. http://www.ispor.org/peguidelines/source/Germany_WorkPaperCostEst.pdf, p. 12. Accessed September 4, 2015
- Levin R, Degrange M, Porcile R, et al. Preoperative use of calcium sensitizer levosimendan reduces mortality and low cardiac output syndrome in patients with aortic stenosis and left ventricular dysfunction. Circulation 2008;118:E217
- InEK. Fallpauschalen-Katalog 2014. 2014. http://www.g-drg.de/cms/G-DRG-System_2014/Fallpauschalen-Katalog/Fallpauschalen-Katalog_2014. Accessed September 4, 2015
- Statistische Bundesamt. Sterbetafeln 2005/2007, Früheres Bundesgebiet und neue Länder. 2009. https://www.destatis.de/DE/Publikationen/Thematisch/Bevoelkerung/Bevoelkerungsbewegung/PeriodensterbetafelnPDF_5126202.pdf?__blob=publicationFile, p. 359–70. Accessed September 4, 2015
- National Clinical Guideline Centre. Acute heart failure: diagnosing and managing acute heart failure in adults; Commissioned by the National Institute for Health and Care Excellence. 2014. https://www.nice.org.uk/guidance/cg187/resources/guidance-acute-heart-failure-pdf. Accessed September 4, 2015
- Lahtinen P, Pitkänen O, Pölönen P, et al. Levosimendan reduces heart failure after cardiac surgery: a prospective, randomized, placebo-controlled trial. Crit Care Med 2011;39:2263-70
- Orion Pharma. Levosimendan − Summary of Product Characteristics. Orion Pharma. 2015. http://www.simdax.com/About-Simdax/SPC/. Accessed September 4, 2015
- Electronic Medicines Compendium. Summary of product characteristics: Dobutamine. 2013. http://www.evidence.nhs.uk/bnf/Search?om=[{%22srn%22:[%22electronic%20Medicines%20Compendium%20-%20eMC%22]}]&q=dobutamine&cid=5001. Accessed September 4, 2015
- LAUER-taxe. LAUER-taxe online pharmaceutical pricing database. 2014. http://www2.lauer-fischer.de/produkte/lauer-taxe/webapo-infosystem-english/. Accessed September 4, 2015
- Programm für Nationale VersorgungsLeitlinien. Nationale VersorgungsLeitlinie: Chronische Herzinsuffizienz. 2014. http://www.leitlinien.de/mdb/downloads/nvl/herzinsuffizienz/herzinsuffizienz-1aufl-vers7-lang.pdf. Accessed September 4, 2015
- German Einheitlicher Bemessungsmaβstab (EBM Katalog). 2015. http://www.kbv.de/html/online-ebm.php. Accessed September 4, 2015
- Kassenärztliche Bundesvereinigung. EBM Katalog (Einheitlicher Bemessungsmaβstab). 2015. http://www.kbv.de/media/sp/EBM_Gesamt___Stand_1._Quartal_2015.pdf. Accessed September 4, 2015
- Baysal A, Yanartas M, Dogukan M, et al. Levosimendan improves renal outcome in cardiac surgery: A randomized trial. J Cardiothorac Vasc Anesth 2014;28:586-94
- Balzer F, Treskatsch S, Spies C, et al. Early administration of levosimendan is associated with improved kidney function after cardiac surgery inverted question mark a retrospective analysis. J Cardiothorac Surg 2014;9:167
- Alvarez J, Baluja A, Selas S, et al. A comparison of dobutamine and levosimendan on hepatic blood flow in patients with a low cardiac output state after cardiac surgery: a randomised controlled study. Anaesth Intensive Care 2013;41:719-27
- Ersoy O, Boysan E, Unal EU, et al. Effectiveness of prophylactic levosimendan in high-risk valve surgery patients. Cardiovasc J Afr 2013;24:260-4
- Levin RL, Degrange MA, Porcile R, et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome. Rev Esp Cardiol 2008;61:471-9
- de Lissovoy G, Fraeman K, Salon J, et al. The costs of treating acute heart failure: an economic analysis of the SURVIVE trial. J Med Econ 2008;11:415-29
- Doorduin J, Sinderby CA, Beck J, et al. The calcium sensitizer levosimendan improves human diaphragm function. Am J Respir Crit Care Med 2012;185:90-5
- Ouanes-Besbes L, Ouanes I, Dachraoui F, et al. Weaning difficult-to-wean chronic obstructive pulmonary disease patients: a pilot study comparing initial hemodynamic effects of levosimendan and dobutamine. J Crit Care 2011;26:15-21
- Sterba M, Banerjee A, Mudaliar Y. Prospective observational study of levosimendan and weaning of difficult-to-wean ventilator dependent intensive care patients. Crit Care Resusc 2008;10:182-6
- Kastrup M, Markewitz A, Spies C, et al. Current practice of hemodynamic monitoring and vasopressor and inotropic therapy in post-operative cardiac surgery patients in Germany: results from a postal survey. Acta Anaesthesiol Scand 2007;51:347-58
- Kastrup M, Braun J, Kaffarnik M, et al. Catecholamine dosing and survival in adult intensive care unit patients. World J Surg 2013;37:766-73